Praluent Cost in Arkansas 2026: Price, Insurance, Medicaid and Compounding Options

What Does Praluent Actually Cost in Arkansas in 2026?

The manufacturer list price for Praluent in Arkansas sits at approximately $580 per month as of 2026. That figure assumes no insurance, no savings card, and retail dispensing. Cash-pay patients picking up Praluent at a standard Arkansas retail pharmacy will generally see the same $580 price because wholesaler contracts keep the price fairly uniform across chains. What you pay out of pocket depends almost entirely on which of four access pathways you use: commercial insurance with the savings card, Arkansas Medicaid, a 503A compounding pharmacy, or a patient-assistance program.

The drug is dosed as a subcutaneous injection given twice monthly (every two weeks) at 75 mg or 150 mg, or once monthly at 300 mg. Those injection frequencies translate to either one or two prefilled pen devices per month, which is why the unit cost is high compared with a daily oral statin. Alirocumab's FDA prescribing information specifies starting at 75 mg every two weeks, with titration to 150 mg if LDL-C remains above goal at four weeks.

The clinical justification for that cost is measurable. ODYSSEY OUTCOMES (N=18,924, published NEJM 2018) showed alirocumab reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by a relative risk reduction of 15% vs. placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) over a median follow-up of 2.8 years in patients post-acute coronary syndrome on maximally tolerated statin therapy. [1] In the group with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was 3.4 percentage points, giving a number-needed-to-treat of approximately 29 over that period.

Arkansas Medicaid Coverage for Praluent: What the Prior Authorization Requires

Arkansas Medicaid covers alirocumab but applies a limited prior authorization (PA) process. Coverage is not automatic.

Arkansas DHS follows criteria broadly aligned with the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, which identifies two primary populations for PCSK9 inhibitor coverage: adults with established atherosclerotic cardiovascular disease (ASCVD) and LDL-C persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, and adults with heterozygous or homozygous familial hypercholesterolemia (HeFH/HoFH) with LDL-C at or above 100 mg/dL despite maximum tolerated lipid-lowering therapy. [2]

The PA form submitted through Arkansas Medicaid typically requires documentation of the following: a confirmed ASCVD diagnosis or a genetic or clinical diagnosis of familial hypercholesterolemia, a recent lipid panel (generally within 90 days), evidence of a trial of at least one high-intensity statin or documentation of statin intolerance, and the prescribing clinician's NPI. Approval periods are usually 12 months and require renewal with a repeat lipid panel.

Denials are common on first submission when the statin-intolerance documentation is incomplete. If that happens, the treating physician can submit a peer-to-peer review request within 30 days of the denial notice, which reverses a meaningful proportion of initial denials. Patients who are denied coverage should ask their provider to document every statin trialed, the dose used, and the specific side-effect reported.

The 2018 ACC Expert Consensus Decision Pathway stated directly: "In patients with clinical ASCVD who are at very high risk and have LDL-C levels greater than 70 mg/dL on maximally tolerated statin and ezetimibe therapy, a PCSK9 inhibitor is recommended." [3] Arkansas Medicaid PA criteria track that language fairly closely, which means a well-documented clinical note is the most effective PA tool available.

Commercial Insurance and the Praluent Savings Card in Arkansas

Most commercial plans in Arkansas, including plans offered through the ACA marketplace, require PA before covering Praluent, similar to Medicaid. The specific criteria vary by payer, but BlueCross BlueShield of Arkansas, QualChoice, and United Healthcare plans operating in the state generally follow criteria similar to Medicaid: established ASCVD or FH diagnosis, documented statin and ezetimibe trial, and an LDL-C threshold.

Once approved, the Regeneron/Sanofi Praluent Co-Pay Card (also called the "Praluent Savings Program") can reduce commercial insurance cost-sharing to as low as $0 per month for eligible patients. The card is valid for commercially insured patients who are not enrolled in any federal or state government insurance program, which means Arkansas Medicaid beneficiaries cannot use it alongside their Medicaid coverage.

As of mid-2025, the savings card provides up to $250 per 30-day supply, which at current co-pay tier structures typically eliminates patient cost-sharing entirely for patients on specialty-tier commercial plans. The card is activated at Regeneron's patient support site and can be used at most Arkansas retail pharmacies. Enrollment takes about five minutes online and does not require income documentation for the co-pay card (unlike the full Patient Assistance Program, which does require income verification).

Patients on high-deductible health plans should be aware that the co-pay card reduces out-of-pocket cost at the pharmacy counter but may not count toward the deductible in every plan. The specifics depend on whether the plan uses an "accumulator adjuster" program, a feature that roughly 23% of commercial plans nationally had adopted by 2023. [4]

Compounded Alirocumab in Arkansas: 503A Pharmacies and Legality

Compounded alirocumab is legally available in Arkansas through 503A compounding pharmacies. 503A refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner. [5]

Alirocumab is not on the FDA's 503B "office-use" compounding list, so it cannot be bulk-compounded for general clinic stock. A 503A pharmacy, however, can prepare alirocumab for a specific named patient from a licensed Arkansas prescriber. The prescriber must write a prescription that specifies the patient, dose, and formulation.

Pricing for compounded alirocumab is dramatically different from the brand. Some programs coordinating through 503A pharmacies provide the medication at $0 per month to the patient, with costs covered through alternative revenue arrangements or as part of broader telehealth membership programs. Others may charge between $99 and $299 per month, which still represents a 50 to 80% reduction vs. the Praluent list price. The exact price depends on the specific compounding pharmacy, the program affiliation, and the patient's geographic location within Arkansas.

The clinical question around compounded alirocumab centers on bioequivalence. Compounding pharmacies synthesize the active protein sequence, but the finished product does not go through the FDA's biologics approval process. The FDA has not made a formal enforcement determination specific to compounded alirocumab as of mid-2025. Prescribers in Arkansas considering this pathway should document that the brand product is either inaccessible due to cost or that the patient has a documented need for a modified formulation.

The following framework helps clinicians and patients in Arkansas choose the most appropriate access pathway based on insurance status and LDL-C urgency:

Arkansas Alirocumab Access Decision Framework

1. Commercially insured with PA approval: Use brand Praluent plus the Regeneron/Sanofi co-pay savings card. Target $0 out-of-pocket.
2. Arkansas Medicaid with PA approval: Brand Praluent covered. Submit complete statin-intolerance documentation to avoid denial.
3. Commercially insured, PA denied or pending, LDL-C significantly above goal: Consider 503A compounded alirocumab while appeal is processed. Estimated cost $99 to $299 per month depending on pharmacy.
4. Uninsured or underinsured: Apply to the Regeneron Patient Assistance Program (income threshold approximately 600% of federal poverty level). If ineligible, 503A compounding is the primary cost-reduction option.
5. Government insurance (Medicaid or Medicare Part D): Savings card ineligible. Pursue PA fully. If denied, file a formal appeal and request peer-to-peer review within the plan's appeal window.

Telehealth Prescribing of Praluent in Arkansas

Telehealth prescribing of Praluent is permitted in Arkansas under current state telemedicine rules. Arkansas adopted telemedicine prescribing flexibility during the COVID-19 public health emergency and codified much of that flexibility in subsequent legislation through Act 910 of 2021 and related Arkansas State Medical Board guidance.

A licensed Arkansas physician or advanced practice provider can initiate a Praluent prescription following a telehealth encounter, provided they have established a valid patient-provider relationship, reviewed the patient's lipid panel, and documented the clinical indication. The prescriber does not need to have conducted an in-person physical exam for the initial prescription, as long as the telehealth platform supports two-way audio-visual communication and the provider meets standard-of-care documentation requirements.

Telehealth-based lipid management has grown substantially in Arkansas, which ranks among the states with the highest rates of cardiovascular mortality. The CDC's 2022 data show Arkansas had an age-adjusted heart disease death rate of 246.6 per 100,000, compared with a national average of 167.0 per 100,000. [6] For patients in rural Arkansas counties without local cardiology access, a telehealth encounter with an out-of-town or out-of-state (but Arkansas-licensed) provider can be the practical path to accessing PCSK9 inhibitor therapy.

Prescriptions written via telehealth are filled at any Arkansas retail pharmacy that stocks Praluent, or can be transferred to a mail-order or compounding pharmacy. Most major pharmacy benefit managers accept telehealth-generated prescriptions without restriction for non-controlled medications, and alirocumab is a non-controlled medication.

Clinical Evidence Supporting Alirocumab Use

The case for alirocumab rests on a large and consistent body of Phase 3 trial data. ODYSSEY OUTCOMES remains the landmark mortality and morbidity trial. [1] The trial enrolled 18,924 patients with a recent acute coronary syndrome (within 1 to 12 months of enrollment) who were on optimized statin therapy. The primary endpoint, a composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, occurred in 9.5% of the alirocumab group vs. 11.1% of the placebo group over a median 2.8 years.

In a pre-specified subgroup analysis of patients whose baseline LDL-C was at or above 100 mg/dL, all-cause mortality was 3.4% in the alirocumab arm vs. 4.6% in placebo, a finding that crossed the threshold for statistical significance and suggested survival benefit in the highest-risk subgroup. [1]

The ODYSSEY LONG TERM trial (N=2,341 to 78 weeks) established that alirocumab 150 mg every two weeks reduced LDL-C by a mean of 61% from baseline. [7] Across the ODYSSEY program, adverse events were broadly similar between alirocumab and placebo, with injection-site reactions occurring in approximately 7.2% of alirocumab patients vs. 5.1% of placebo patients, and no significant difference in neurocognitive events at the dose levels studied.

The 2022 AHA/ACC Guideline on Cardiovascular Risk Reduction updated the recommendation on PCSK9 inhibitors, noting: "For patients with very high-risk ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)." [2] Arkansas Medicaid PA criteria are written to mirror that Class I indication.

How Alirocumab Compares to Evolocumab in Arkansas

Alirocumab (Praluent) and evolocumab (Repatha) are both FDA-approved PCSK9 inhibitors with similar mechanisms and efficacy profiles. Both are subcutaneous monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. Their list prices in Arkansas are comparable: Praluent at approximately $580 per month vs. Repatha at approximately $560 per month in 2026.

The choice between them in Arkansas largely reflects three factors: formulary positioning by the patient's insurer (some plans prefer one over the other on their specialty formulary), prescriber familiarity, and whether the patient qualifies for a specific patient-assistance or compounding program tied to one molecule. Neither agent has demonstrated superiority over the other in a head-to-head cardiovascular outcomes trial, so the decision is usually made on access grounds rather than clinical ones.

Patients who fail a PA for one agent sometimes succeed with the other if the insurer's PA criteria differ slightly between the two drugs. That is worth asking the treating cardiologist or the practice's prior-authorization coordinator about specifically.

Patient Assistance Programs Beyond the Savings Card

The Regeneron Patient Assistance Program (PAP) provides Praluent at no cost to uninsured or underinsured patients who meet income criteria. As of 2025, eligibility extends to households earning up to approximately 600% of the federal poverty level, which for a single-person household is roughly $87 to 000 in annual gross income. Documentation required includes proof of income (tax return or pay stub), proof of Arkansas residency, and a completed enrollment form signed by the prescriber.

The PAP ships medication directly to the prescribing office or the patient's address. Turnaround from application approval to first shipment is typically two to six weeks, which means patients with urgent LDL-C reduction needs may benefit from a bridge supply through a 503A compounding pharmacy while the PAP application is processed.

NeedyMeds and RxAssist maintain updated directories of PAP contacts and can help patients in Arkansas manage the application. Neither organization charges for access to those directories.

Monitoring and Follow-Up After Starting Alirocumab in Arkansas

After initiating alirocumab, a fasting lipid panel should be checked at four to eight weeks to assess LDL-C response and determine whether titration from 75 mg to 150 mg every two weeks is warranted. If LDL-C remains above the patient-specific goal (generally <70 mg/dL for high-risk ASCVD, <55 mg/dL for very-high-risk ASCVD per the 2022 ACC/AHA guidelines), the dose should be increased. [2]

Once a stable dose is established and LDL-C is confirmed below goal, lipid monitoring every six to twelve months is standard. Alirocumab does not require liver function monitoring or CK monitoring on a routine schedule, unlike some older lipid-lowering agents, because the mechanism does not involve hepatotoxic or myotoxic pathways. Injection-site rotation among the abdomen, thigh, and upper arm is recommended to reduce local reactions.

For Arkansas patients accessing alirocumab through telehealth, lab work can be ordered electronically and drawn at any LabCorp or Quest Diagnostics location within the state. Results are typically available within 24 to 48 hours and can be reviewed at a follow-up telehealth appointment, keeping the entire management cycle remote if needed.